Merck KGaA, Threshold drug fails in late-stage cancer trials

Reuters FRANKFURT | Updated on January 22, 2018 Published on December 07, 2015

Germany's Merck KGaA and development partner Threshold Pharmaceuticals said their experimental cancer drug Evofosfamide failed to show the desired effects in two late stage studies.

Evofosfamide did not meet the main goal of improving overall survival in patients suffering from advanced pancreatic cancer and advanced soft tissue sarcoma, prompting the two companies to give up exploring the drug's use against the these cancer forms.

Merck said it would soon decide over the drug's future overall.

Published on December 07, 2015
This article is closed for comments.
Please Email the Editor